445 related articles for article (PubMed ID: 16178046)
1. Frequency of high-risk use of QT-prolonging medications.
Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic agents associated with QT interval prolongation.
Olsen KM
J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced torsades de pointes in patients aged 80 years or more.
Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
[TBL] [Abstract][Full Text] [Related]
4. Long QT syndrome caused by noncardiac drugs.
Viskin S; Justo D; Halkin A; Zeltser D
Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
[TBL] [Abstract][Full Text] [Related]
5. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
[TBL] [Abstract][Full Text] [Related]
6. [Why is QT interval interesting?].
Elming H; Sonne J; Lublin HK
Ugeskr Laeger; 2002 Feb; 164(6):750-4. PubMed ID: 11851179
[TBL] [Abstract][Full Text] [Related]
7. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
9. Proarrhythmic potential of antimicrobial agents.
Simkó J; Csilek A; Karászi J; Lorincz I
Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
[TBL] [Abstract][Full Text] [Related]
10. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
Lin YL; Kung MF
Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
[TBL] [Abstract][Full Text] [Related]
11. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
Wolbrette D
Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ; Roden DM
Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced q-T prolongation.
Kao LW; Furbee RB
Med Clin North Am; 2005 Nov; 89(6):1125-44, x. PubMed ID: 16227057
[TBL] [Abstract][Full Text] [Related]
15. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
16. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
17. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
18. Male/female differences in pharmacology: safety issues with QT-prolonging drugs.
Anthony M
J Womens Health (Larchmt); 2005; 14(1):47-52. PubMed ID: 15692277
[TBL] [Abstract][Full Text] [Related]
19. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.
Smithburger PL; Seybert AL; Armahizer MJ; Kane-Gill SL
Expert Opin Drug Saf; 2010 Sep; 9(5):699-712. PubMed ID: 20377471
[TBL] [Abstract][Full Text] [Related]
20. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
Hashimoto K
Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]